WW domain-containing oxidoreductase promotes neuronal differentiation via negative regulation of glycogen synthase kinase 3Β

Cell Death and Differentiation

Volumn 19, Issue 6, 2012, Pages 1049-1059

  Wang, H Y ^a   Juo, L I ^a   Lin, Y T ^b   Hsiao, M ^c   Lin, J T ^b   Tsai, C H ^a   Tzeng, Y H ^a   Chuang, Y C ^d   Chang, N S ^a   Yang, C N ^d   Lu, P J ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL UNIVERSITY OF KAOHSIUNG   (Taiwan)

Author keywords

GSK3 ; SH SY5Y; Tau; WWOX

Indexed keywords

ALCOHOL DEHYDROGENASE; GLYCOGEN SYNTHASE KINASE 3BETA; OXIDOREDUCTASE; TAU PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; MICROTUBULE; NERVE CELL DIFFERENTIATION; NERVE FIBER GROWTH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; BINDING SITES; CELL LINE, TUMOR; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICROTUBULES; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; NEUROGENESIS; NEURONS; OXIDOREDUCTASES; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RNA INTERFERENCE; RNA, SMALL INTERFERING; TAU PROTEINS; TRETINOIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84860780063     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.188     Document Type: Article

References (28)

1. Paige AJ, Taylor KJ, Taylor C, Hillier SG, Farrington S, Scott D et al. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc Natl Acad Sci USA 2001; 98: 11417-11422.
2. Sze CI, Su M, Pugazhenthi S, Jambal P, Hsu LJ, Heath J et al. Down-regulation of WW domain-containing oxidoreductase induces Tau phosphorylation in vitro. A potential role in Alzheimer's disease. J Biol Chem 2004; 279: 30498-30506.
3. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007; 17: 31-41.
4. Gourley C, Paige AJ, Taylor KJ, Ward C, Kuske B, Zhang J et al. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3. Cancer Res 2009; 69: 4835-4842.
5. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 2004; 64: 8256-8261.
6. Chang NS, Hsu LJ, Lin YS, Lai FJ, Sheu HM. WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med 2007; 13: 12-22.
7. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 2003; 116(Part 7): 1175-1186.
8. Hedgepeth CM, Deardorff MA, Rankin K, Klein PS. Regulation of glycogen synthase kinase 3beta and downstream Wnt signaling by axin. Mol Cell Biol 1999; 19: 7147-7157.
9. Chou HY, Howng SL, Cheng TS, Hsiao YL, Lieu AS, Loh JK et al. GSKIP is homologous to the Axin GSK3beta interaction domain and functions as a negative regulator of GSK3beta. Biochemistry 2006; 45: 11379-11389.
10. Zhou F, Zhang L, Wang A, Song B, Gong K, Zhang L et al. The association of GSK3 beta with E2F1 facilitates nerve growth factor-induced neural cell differentiation. J Biol Chem 2008; 283: 14506-14515.
11. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005; 120: 137-149.
12. Chen ST, Chuang JI, Wang JP, Tsai MS, Li H, Chang NS. Expression of WW domaincontaining oxidoreductase WOX1 in the developing murine nervous system. Neuroscience 2004; 124: 831-839.
13. Maden M. Retinoid signalling in the development of the central nervous system. Nat Rev 2002; 3: 843-853.
14. Clagett-Dame M, McNeill EM, Muley PD. Role of all-trans retinoic acid in neurite outgrowth and axonal elongation. J Neurobiol 2006; 66: 739-756.
15. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neurochem 2000; 75: 991-1003.
16. Hernandez F, Lucas JJ, Cuadros R, Avila J. GSK-3 dependent phosphoepitopes recognized by PHF-1 and AT-8 antibodies are present in different tau isoforms. Neurobiol Aging 2003; 24: 1087-1094.
17. Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM et al. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res 2006; 66: 11585-11589.
18. Tang XN, Lo CW, Chuang YC, Chen CT, Sun YC, Hong YR et al. Prediction of the binding mode between GSK3b and a peptide derived from GSKIP using molecular dynamics simulation. Biopolymers 2011; 95: 461-471.
19. Dajani R, Fraser E, Roe SM, Yeo M, Good VM, Thompson V et al. Structural basis for recruitment of glycogen synthase kinase 3beta to the axin-APC scaffold complex. EMBO J 2003; 22: 494-501.
20. Utton MA, Vandecandelaere A, Wagner U, Reynolds CH, Gibb GM, Miller CC et al. Phosphorylation of tau by glycogen synthase kinase 3beta affects the ability of tau to promote microtubule self-assembly. Biochem J 1997; 323(Part 3): 741-747.
21. Ahmad FJ, Joshi HC, Centonze VE, Baas PW. Inhibition of microtubule nucleation at the neuronal centrosome compromises axon growth. Neuron 1994; 12: 271-280.
22. Wagner U, Utton M, Gallo JM, Miller CC. Cellular phosphorylation of tau by GSK-3 beta influences tau binding to microtubules and microtubule organisation. J Cell Sci 1996; 109 (Part 6): 1537-1543.
23. Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res 2007; 32: 577-595.
24. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55.
25. Goold RG, Gordon-Weeks PR. The MAP kinase pathway is upstream of the activation of GSK3beta that enables it to phosphorylate MAP1B and contributes to the stimulation of axon growth. Mol Cell Neurosci 2005; 28: 524-534.
26. Gompel M, Soulie C, Ceballos-Picot I, Meijer L. Expression and activity of cyclin-dependent kinases and glycogen synthase kinase-3 during NT2 neuronal differentiation. Neuro-Signals 2004; 13: 134-143.
27. Castano Z, Gordon-Weeks PR, Kypta RM. The neuron-specific isoform of glycogen synthase kinase-3beta is required for axon growth. J Neurochem 2011; 113: 117-130.
28. Garnier J, Gibrat JF, Robson B. GOR method for predicting protein secondary structure from amino acid sequence. Methods Enzymol 1996; 266: 540-553.